Background: Soluble CD4 and its more bioavailable form, CD4-Ig, neutralize HIV-1 less potently than most broadly neutralizing antibodies (bNAbs) because they bind the HIV-1 envelope glycoprotein with lower affinity and promote infection when cellular CD4 is limiting. Methodology: We generated a fusion of CD4-Ig and a small CCR5-mimetic sulfopeptide (eCD4-Ig) and compared this fusion with CD4-Ig and the broadest and most potent bNAbs. We also investigated its properties in vivo. Results: eCD4-Ig overcomes both shortcomings of CD4-Ig: It bound the envelope glycoprotein with higher avidity than CD4-Ig and its sulfopeptide inhibited infection promoted by CD4-Ig. eCD4-Ig efficiently neutralized a diverse panel of antibody-resistant tier 2 and tier 3 isolates without exception and with IC50s ranging from 0.002 to 1.137 μg/ml (0.02-11 nM) − values comparable to or better than those of the best HIV-1 bNAbs. Because it binds only conserved regions of the HIV-1 envelope glycoprotein, it is also broader than any bNab. Underscoring this breadth, it neutralized all forty isolates resistant to CD4-binding site bNAbs NIH45-46 and 3BCN117, as well as HIV-2 and antibody resistant SIV isolates, with IC50s from 0.001 to 1.453 μg/ ml. eCD4-Ig also induced markedly more efficient antibody-dependent killing of HIV-1- or SIV-infected cells than did CD4-Ig and protected humanized mice from an HIV-1 challenge. Further, it retained its efficacy when delivered as an adeno-associated virus vector to three rhesus macaques, without eliciting an anti-eCD4-Ig antibody response. Conclusions: eCD4-Ig is a highly potent, exceptionally broad, and mechanistically distinct inhibitor of HIV-1 entry that can be used to prevent or treat an HIV-1 infection.